Prospective Grant of Exclusive License: Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers and Methods and Kits for Targeting, 40385-40386 [05-13804]
Download as PDF
<![CDATA[
[FR Doc. 05–13706 Filed 7–12–05; 8:45 am]
BILLING CODE 4160–01–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Mesothelin, a Differentiation
Antigen Present on Mesothelium,
Mesotheliomas and Ovarian Cancers
and Methods and Kits for Targeting
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
No. 60/010,166, filed January 5, 1996,
entitled ‘‘Mesothelin, A Differentiation
Antigen Present On Mesothelium,
Mesotheliomas And Ovarian Cancers
VerDate jul<14>2003
17:40 Jul 12, 2005
Jkt 205001
And Methods And Kits For Targeting’’
[E–002–1996/0–US–01]; United States
Patent No. 6,153,430, issued on
November 28, 2000, entitled ‘‘Nucleic
Acid Encoding Mesothelin, A
Differentiation Antigen Present On
Mesothelium, Mesotheliomas And
Ovarian Cancers’’ [E–002–1996/0–US–
02]; United States Patent Application
No. 09/684,599, filed October 5, 2000,
entitled ‘‘Mesothelin, A Differentiation
Antigen Present On Mesothelium,
Mesotheliomas And Ovarian Cancers
And Methods And Kits For Targeting’’
(E–002–1996/0–US–03); United States
Patent No. 6,083,502, issued on July 4,
2000, entitled ‘‘Mesothelium Antigen
And Methods And Kits For Targeting It’’
[E–002–1996/1–US–02]; PCT
Application No. PCT/US97/00224, filed
January 3, 1997, entitled ‘‘Mesothelium
Antigen And Methods And Kits For
Targeting It’’ [E–002–1996/1–PCT–01];
Australian Patent No. 703769, filed
January 3, 1997, entitled ‘‘Mesothelium
Antigen And Methods And Kits For
Targeting It’’ [E–002–1996/1–AU–03];
Canadian Patent No. 2241604, filed
January 3, 1997, entitled ‘‘Mesothelium
Antigen And Methods And Kits For
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
40385
Targeting It’’ [E–002–1996/1–CA–04];
Japanese Patent Application No. 9–
525355, filed January 3, 1997, entitled
‘‘Mesothelium Antigen And Methods
And Kits For Targeting It’’ [E–002–1996/
1–JP–06]; European Patent No. 0871492,
filed January 3, 1997, entitled
‘‘Mesothelium Antigen And Methods
And Kits For Targeting It’’ [E–002–1996/
1–EP–05]; Switzerland Patent
Application No. 0871492, filed January
3, 1997, entitled ‘‘Mesothelium Antigen
And Methods And Kits For Targeting It’’
[E–002–1996/1–CH–07]; German Patent
No. 69726404.1, filed January 3, 1997,
entitled ‘‘Mesothelium Antigen And
Methods And Kits For Targeting It’’ (E–
002–1996/1–DE–08); French Patent
Application No. 0871492, filed January
3, 1997, entitled ‘‘Mesothelium Antigen
And Methods And Kits For Targeting It’’
[E–002–1996/1–FR–09]; Italian Patent
No. 05503/BE/2004, January 3, 1997,
entitled ‘‘Mesothelium Antigen And
Methods And Kits For Targeting It’’ [E–
002–1996/1-–T–10]; Spanish Patent No.
0871492, filed January 3, 1997, entitled
‘‘Mesothelium Antigen And Methods
And Kits For Targeting It’’ [E–002–1996/
1–ES–11]; United Kingdom Patent No.
E:\FR\FM\13JYN1.SGM
13JYN1
EN13JY05.164</GPH>
Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices
40386
Federal Register / Vol. 70, No. 133 / Wednesday, July 13, 2005 / Notices
0871492, filed January 3, 1997, entitled
‘‘Mesothelium Antigen And Methods
And Kits For Targeting It’’ [E–002–1996/
1–GB–12]; United States Patent No.
5,320,956, issued June 14, 1996, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–US–20]; United States Patent No.
5,525,337, issued June 11, 1996, entitled
‘‘Monoclonal Antibody Binding Cell
Surface Antigen For Diagnosing Cancer’’
[E–195–1990/0–US–21]; United States
Patent No. 5,817,313, issued October 6,
1998, entitled ‘‘Monoclonal Antibodies
And Conjugates Thereof Useful For The
Treatment Of Cancer’’ [E–195–1990/0–
US–22]; PCT Patent Application No.
PCT/US91/07227, filed October 9, 1991,
entitled ‘‘Monoclonal Antibody’’ [E–
195–1990/0–PCT–02]; Denmark Patent
No. 0554356, filed October 9, 1991,
entitled ‘‘Monoclonal Antibody’’ [E–
195–1990/0–DK–03]; United Kingdom
Patent No. 0554356, filed October 9,
1991, entitled ‘‘Monoclonal Antibody’’
[E–195–1990/0–GB–04]; Austrian Patent
No. 0554356, filed October 9, 1991,
entitled ‘‘Monoclonal Antibody’’ [E–
195–1990/0–AT–05]; Belgium Patent
No. 0554356, filed October 9, 1991,
entitled ‘‘Monoclonal Antibody’’ [E–
195–1990/0–BE–06]; European Patent
No. 0554356, filed October 9, 1991,
entitled ‘‘Monoclonal Antibody’’ [E–
195–1990/0–EP–09]; French Patent No.
0554356, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–FR–11]; German Patent No. 0554356,
filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–DE–08]; Greece Patent No. 0554356,
filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–GR–12]; Netherlands Patent No.
0554356, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–NL–15]; Italian Patent No. 0554356,
filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–IT–13]; Luxembourg Patent No.
0554356, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–LU–14]; Spanish Patent No. 0554356,
filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0-ES–10]; Sweden Patent No. 0554356,
filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–SE–16]; Switzerland Patent No.
0554356, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–CH–07]; Australian Patent No.
648363, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–AU–17]; Canadian Patent No.
2093928, filed October 9, 1991, entitled
‘‘Monoclonal Antibody’’ [E–195–1990/
0–CA–18]; and Japanese Patent No.
2660241, filed October 9, 1991, entitled
VerDate jul<14>2003
17:40 Jul 12, 2005
Jkt 205001
‘‘Monoclonal Antibody’’ [E–195–1990/
0–JP–19] to Morphotek, Inc., which has
offices in Exton, Pennsylvania. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the use
of licensee’s MORAb–009 antibody for
the treatment of mesothelin-expressing
cancer.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
September 12, 2005 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Jesse S. Kindra, J.D.,
M.S., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5559; Facsimile: (301) 402–0220; E-mail:
kindraj@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
technology relates to CAK1, or
‘‘mesothelin’’, which is an antigen
present on the cell surface in
mesothelium and on many
mesotheliomas and ovarian cancers.
While the role of this differentiation
antigen has not yet been determined, it
is postulated that it may be implicated
in adhesion and in the dissemination of
mesotheliomas and of ovarian cancers.
CAK1, therefore, is a potential target for
monoclonal antibodies to be used in the
diagnosis and treatment of these
cancers. The gene for CAK1 has been
cloned and sequenced, as embodied in
the current technology. This technology,
therefore, should provide a valuable
research tool for use in the development
of diagnostics and/or therapeutic agents
toward mesotheliomas and ovarian
cancers.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: July 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–13804 Filed 7–12–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Centers of
Cancer Nanotechnology Excellence (CCNEs).
Date: July 19–22, 2005.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Georgetown, 2101
Wisconsin Ave NW., Washington, DC 20007.
Contact Person: Michael B. Small, PhD,
Scientific Review Administrator, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, National Institutes of Health, 6116
Executive Blvd., Room 8127, Bethesda, MD
20892–8328, 301–402–0996,
smallm@mail.nih.gov.
This notice is published less than 15 days
prior to meeting due to scheduling conflicts.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
E:\FR\FM\13JYN1.SGM
13JYN1
]]>Agencies
[Federal Register Volume 70, Number 133 (Wednesday, July 13, 2005)]
[Notices]
[Pages 40385-40386]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-13804]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Mesothelin, a
Differentiation Antigen Present on Mesothelium, Mesotheliomas and
Ovarian Cancers and Methods and Kits for Targeting
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
Patent Application No. 60/010,166, filed January 5, 1996, entitled
``Mesothelin, A Differentiation Antigen Present On Mesothelium,
Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting''
[E-002-1996/0-US-01]; United States Patent No. 6,153,430, issued on
November 28, 2000, entitled ``Nucleic Acid Encoding Mesothelin, A
Differentiation Antigen Present On Mesothelium, Mesotheliomas And
Ovarian Cancers'' [E-002-1996/0-US-02]; United States Patent
Application No. 09/684,599, filed October 5, 2000, entitled
``Mesothelin, A Differentiation Antigen Present On Mesothelium,
Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting''
(E-002-1996/0-US-03); United States Patent No. 6,083,502, issued on
July 4, 2000, entitled ``Mesothelium Antigen And Methods And Kits For
Targeting It'' [E-002-1996/1-US-02]; PCT Application No. PCT/US97/
00224, filed January 3, 1997, entitled ``Mesothelium Antigen And
Methods And Kits For Targeting It'' [E-002-1996/1-PCT-01]; Australian
Patent No. 703769, filed January 3, 1997, entitled ``Mesothelium
Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-AU-03];
Canadian Patent No. 2241604, filed January 3, 1997, entitled
``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-
1996/1-CA-04]; Japanese Patent Application No. 9-525355, filed January
3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For
Targeting It'' [E-002-1996/1-JP-06]; European Patent No. 0871492, filed
January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits
For Targeting It'' [E-002-1996/1-EP-05]; Switzerland Patent Application
No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And
Methods And Kits For Targeting It'' [E-002-1996/1-CH-07]; German Patent
No. 69726404.1, filed January 3, 1997, entitled ``Mesothelium Antigen
And Methods And Kits For Targeting It'' (E-002-1996/1-DE-08); French
Patent Application No. 0871492, filed January 3, 1997, entitled
``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-
1996/1-FR-09]; Italian Patent No. 05503/BE/2004, January 3, 1997,
entitled ``Mesothelium Antigen And Methods And Kits For Targeting It''
[E-002-1996/1--T-10]; Spanish Patent No. 0871492, filed January 3,
1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting
It'' [E-002-1996/1-ES-11]; United Kingdom Patent No.
[[Page 40386]]
0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And
Methods And Kits For Targeting It'' [E-002-1996/1-GB-12]; United States
Patent No. 5,320,956, issued June 14, 1996, entitled ``Monoclonal
Antibody'' [E-195-1990/0-US-20]; United States Patent No. 5,525,337,
issued June 11, 1996, entitled ``Monoclonal Antibody Binding Cell
Surface Antigen For Diagnosing Cancer'' [E-195-1990/0-US-21]; United
States Patent No. 5,817,313, issued October 6, 1998, entitled
``Monoclonal Antibodies And Conjugates Thereof Useful For The Treatment
Of Cancer'' [E-195-1990/0-US-22]; PCT Patent Application No. PCT/US91/
07227, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-
1990/0-PCT-02]; Denmark Patent No. 0554356, filed October 9, 1991,
entitled ``Monoclonal Antibody'' [E-195-1990/0-DK-03]; United Kingdom
Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal
Antibody'' [E-195-1990/0-GB-04]; Austrian Patent No. 0554356, filed
October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AT-05];
Belgium Patent No. 0554356, filed October 9, 1991, entitled
``Monoclonal Antibody'' [E-195-1990/0-BE-06]; European Patent No.
0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-
195-1990/0-EP-09]; French Patent No. 0554356, filed October 9, 1991,
entitled ``Monoclonal Antibody'' [E-195-1990/0-FR-11]; German Patent
No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody''
[E-195-1990/0-DE-08]; Greece Patent No. 0554356, filed October 9, 1991,
entitled ``Monoclonal Antibody'' [E-195-1990/0-GR-12]; Netherlands
Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal
Antibody'' [E-195-1990/0-NL-15]; Italian Patent No. 0554356, filed
October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-IT-13];
Luxembourg Patent No. 0554356, filed October 9, 1991, entitled
``Monoclonal Antibody'' [E-195-1990/0-LU-14]; Spanish Patent No.
0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-
195-1990/0-ES-10]; Sweden Patent No. 0554356, filed October 9, 1991,
entitled ``Monoclonal Antibody'' [E-195-1990/0-SE-16]; Switzerland
Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal
Antibody'' [E-195-1990/0-CH-07]; Australian Patent No. 648363, filed
October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AU-17];
Canadian Patent No. 2093928, filed October 9, 1991, entitled
``Monoclonal Antibody'' [E-195-1990/0-CA-18]; and Japanese Patent No.
2660241, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-
195-1990/0-JP-19] to Morphotek, Inc., which has offices in Exton,
Pennsylvania. The patent rights in these inventions have been assigned
to the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the use of licensee's MORAb-009
antibody for the treatment of mesothelin-expressing cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
September 12, 2005 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 435-5559; Facsimile: (301) 402-0220; E-
mail: kindraj@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology relates to CAK1, or
``mesothelin'', which is an antigen present on the cell surface in
mesothelium and on many mesotheliomas and ovarian cancers. While the
role of this differentiation antigen has not yet been determined, it is
postulated that it may be implicated in adhesion and in the
dissemination of mesotheliomas and of ovarian cancers. CAK1, therefore,
is a potential target for monoclonal antibodies to be used in the
diagnosis and treatment of these cancers. The gene for CAK1 has been
cloned and sequenced, as embodied in the current technology. This
technology, therefore, should provide a valuable research tool for use
in the development of diagnostics and/or therapeutic agents toward
mesotheliomas and ovarian cancers.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless within sixty
(60) days from the date of this published notice, the NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-13804 Filed 7-12-05; 8:45 am]
BILLING CODE 4140-01-P
